Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis

Table 1 Summary of the effects of different classes of antidiabetic drugs on cancer risk

Classes of antidiabetic drugs	Biguanide	Sulfonylureas	Thiazolidinediones	DPP-4i	SGLT-2i	GLP-1RA	Insulin
Any cancer	I	I	I	I	I	I	NA
Lung cancer	II	I	I	I	I	I	II
Bronchial cancer	NA	II	NA	II	I	II	NA
Thyroid cancer	NA	II	II	I	II	I	II
Gastric cancer	II	I	II	I	I	II	II
Pancreatic cancer	I	I	II	I	I	I	II
Rectal cancer	NA	II	II	I	I	II	II
Colon cancer	NA	I	NA	I	I	I	NA
Bladder cancer	II	II	II	I	I	I	I
Prostate cancer	I	I	I	I	I	I	II
Uterine cancer	II	II	II	II	I	I	II
Breast cancer	I	I	I	I	I	I	II
Hepatocellular cancer	II	II	I	NA	II	I	NA
Renal cancer	II	II	II	II	II	I	II
Hematologic cancer	II	II	II	II	II	I	II

I: Antidiabetic drugs are associated with a reduced risk of cancer; II: Antidiabetic drugs have a neutral effect on cancer risk; NA: Not available; DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT-2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonists.